Tobira successfully completes Phase 2b for cenicriviroc AIDS vaccine
The cenicriviroc vaccine is a novel, oral, daily, fixed-dose vaccine against CCR5 and CCR2 late-stage detection of HIV infection. The data of the study was presented at the conference, which took place in Brussels, Belgium.
"The final 48-week data presented today confirm previously reported findings from the primary 24-week analysis presented at the Conference on Retroviruses and Opportunistic Infections 2013," Tobira President and Chief Executive Officer Andrew Hindman said. "These data reinforce the positive results we have observed to date for cenicriviroc and add to our confidence that CVC holds potential to become an important component in the future treatment of HIV. We are also pleased that after reviewing the Phase 2b data the FDA has agreed with Tobira's proposed plan to advance CVC/3TC into Phase 3 clinical development."
Tobira gained approval from the U.S. Food and Drug Administration to begin Phase 3 clinical trials of the vaccine. Phase 3 studies will evaluate the ability of a combination vaccine between cenicriviroc and lamivudine, in the hopes of creating a "backbone."
"The time is right for novel HIV regimens with nucleos(t)ide-sparing backbones" Chelsea HIV Service Director Anton Pozniak said.